$JNJ Q1 today. First opp to see how much damage #COVID19 has made on #medtech #pharma landscape. What growth drivers are there in this current climate, with elective proc down and big M&amp;A deals unlikely https://t.co/sDQdU5F1Ui (especially as #Tachosil now dead in the water)?